Merck: presents results of RSV trial

(CercleFinance.com) - Merck announced the presentation of positive results from the Phase 2b/3 clinical trial evaluating clesrovimab, the company's investigational prophylactic monoclonal antibody designed to protect infants against respiratory syncytial virus (RSV) disease.


In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and hospitalizations associated with RSV-associated lower respiratory tract infections (tertiary endpoint) by over 84% and 90%, respectively, over a 5-month period.

The results, together with interim results from the ongoing phase 3 trial of clesrovimab, were presented at IDWeek 2024, held October 16-19 in Los Angeles, California.

Results from the pivotal phase 2b/3 placebo-controlled trial MK-1654-004 evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants (birth to age 1) met all predefined endpoints, with consistent results at 5 months and 6 months.

These promising results demonstrating a decrease in the incidence of RSV infection, including hospitalizations, underscore the potential for clesrovimab to play an important role in alleviating the ongoing burden of RSV on infants and their families.

Clesrovimab has the potential to become the first and only approved vaccine designed to protect infants with the same single dose, regardless of weight, for the duration of their first RSV season, Merck says.


Copyright (c) 2024 CercleFinance.com. All rights reserved.